Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free IBT Stock Alerts

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 954 -12.00 (-1.24%)
As of 12:25 PM Eastern
Compare

IBT vs. JFJ, TMPL, IHP, SDP, and VEIL

Should you buy International Biotechnology stock or one of its competitors? MarketBeat compares International Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with International Biotechnology include JPMorgan Japanese (JFJ), Temple Bar (TMPL), IntegraFin (IHP), Schroder Investment Trust - Schroder AsiaPacific Fund (SDP), and Vietnam Enterprise (VEIL). These companies are all part of the "asset management" industry.

How does International Biotechnology compare to JPMorgan Japanese?

International Biotechnology (LON:IBT) and JPMorgan Japanese (LON:JFJ) are both small-cap financial services companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

6.9% of International Biotechnology shares are held by institutional investors. Comparatively, 18.9% of JPMorgan Japanese shares are held by institutional investors. 1.1% of International Biotechnology shares are held by insiders. Comparatively, 0.1% of JPMorgan Japanese shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

International Biotechnology has a beta of 0.316, suggesting that its share price is 68% less volatile than the broader market. Comparatively, JPMorgan Japanese has a beta of 0.888, suggesting that its share price is 11% less volatile than the broader market.

JPMorgan Japanese has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than JPMorgan Japanese, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M3.89£37.91M-£3.29N/A
JPMorgan Japanese£245.55M4.96£194.81M£149.065.27

JPMorgan Japanese has a net margin of 97.91% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat JPMorgan Japanese's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
JPMorgan Japanese 97.91%21.61%8.06%

International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.3%. JPMorgan Japanese pays an annual dividend of GBX 8.70 per share and has a dividend yield of 1.1%. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. JPMorgan Japanese pays out 5.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, International Biotechnology and International Biotechnology both had 1 articles in the media. JPMorgan Japanese's average media sentiment score of 1.08 beat International Biotechnology's score of 0.67 indicating that JPMorgan Japanese is being referred to more favorably in the news media.

Company Overall Sentiment
International Biotechnology Positive
JPMorgan Japanese Positive

Summary

JPMorgan Japanese beats International Biotechnology on 10 of the 14 factors compared between the two stocks.

How does International Biotechnology compare to Temple Bar?

International Biotechnology (LON:IBT) and Temple Bar (LON:TMPL) are both small-cap financial services companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

6.9% of International Biotechnology shares are owned by institutional investors. Comparatively, 7.6% of Temple Bar shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by company insiders. Comparatively, 0.4% of Temple Bar shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, International Biotechnology had 1 more articles in the media than Temple Bar. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Temple Bar. International Biotechnology's average media sentiment score of 0.67 beat Temple Bar's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
International Biotechnology Positive
Temple Bar Neutral

International Biotechnology has a net margin of 82.27% compared to Temple Bar's net margin of 82.15%. Temple Bar's return on equity of 27.93% beat International Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Temple Bar 82.15%27.93%7.08%

Temple Bar has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Temple Bar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M3.89£37.91M-£3.29N/A
Temple Bar£281.60M4.20£154.90M£97.004.04

International Biotechnology has a beta of 0.316, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Temple Bar has a beta of 1.1508299, meaning that its stock price is 15% more volatile than the broader market.

International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.3%. Temple Bar pays an annual dividend of GBX 14.25 per share and has a dividend yield of 3.6%. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. Temple Bar pays out 14.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Temple Bar beats International Biotechnology on 10 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to IntegraFin?

IntegraFin (LON:IHP) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

IntegraFin has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than IntegraFin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntegraFin£165.40M6.95£52.54M£15.5022.45
International Biotechnology£78.01M3.89£37.91M-£3.29N/A

In the previous week, IntegraFin and IntegraFin both had 1 articles in the media. International Biotechnology's average media sentiment score of 0.67 beat IntegraFin's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IntegraFin
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
International Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

IntegraFin has a beta of 1.267, indicating that its share price is 27% more volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.316, indicating that its share price is 68% less volatile than the broader market.

IntegraFin presently has a consensus price target of GBX 423, suggesting a potential upside of 21.55%. Given IntegraFin's stronger consensus rating and higher probable upside, equities analysts clearly believe IntegraFin is more favorable than International Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IntegraFin
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
International Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

International Biotechnology has a net margin of 82.27% compared to IntegraFin's net margin of 28.60%. IntegraFin's return on equity of 27.60% beat International Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
IntegraFin28.60% 27.60% 20.29%
International Biotechnology 82.27%27.35%3.57%

IntegraFin pays an annual dividend of GBX 10.50 per share and has a dividend yield of 3.0%. International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.3%. IntegraFin pays out 67.7% of its earnings in the form of a dividend. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

44.1% of IntegraFin shares are owned by institutional investors. Comparatively, 6.9% of International Biotechnology shares are owned by institutional investors. 14.5% of IntegraFin shares are owned by company insiders. Comparatively, 1.1% of International Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

IntegraFin beats International Biotechnology on 13 of the 17 factors compared between the two stocks.

How does International Biotechnology compare to Schroder Investment Trust - Schroder AsiaPacific Fund?

International Biotechnology (LON:IBT) and Schroder Investment Trust - Schroder AsiaPacific Fund (LON:SDP) are both small-cap financial services companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

6.9% of International Biotechnology shares are owned by institutional investors. Comparatively, 17.2% of Schroder Investment Trust - Schroder AsiaPacific Fund shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by company insiders. Comparatively, 0.2% of Schroder Investment Trust - Schroder AsiaPacific Fund shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Schroder Investment Trust - Schroder AsiaPacific Fund has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Schroder Investment Trust - Schroder AsiaPacific Fund, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M3.89£37.91M-£3.29N/A
Schroder Investment Trust - Schroder AsiaPacific Fund£191.10M5.57£121.21M£87.169.61

Schroder Investment Trust - Schroder AsiaPacific Fund has a net margin of 95.12% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat Schroder Investment Trust - Schroder AsiaPacific Fund's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Schroder Investment Trust - Schroder AsiaPacific Fund 95.12%20.01%-1.73%

In the previous week, International Biotechnology and International Biotechnology both had 1 articles in the media. Schroder Investment Trust - Schroder AsiaPacific Fund's average media sentiment score of 1.81 beat International Biotechnology's score of 0.67 indicating that Schroder Investment Trust - Schroder AsiaPacific Fund is being referred to more favorably in the news media.

Company Overall Sentiment
International Biotechnology Positive
Schroder Investment Trust - Schroder AsiaPacific Fund Very Positive

International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.3%. Schroder Investment Trust - Schroder AsiaPacific Fund pays an annual dividend of GBX 12.50 per share and has a dividend yield of 1.5%. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. Schroder Investment Trust - Schroder AsiaPacific Fund pays out 14.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

International Biotechnology has a beta of 0.316, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Schroder Investment Trust - Schroder AsiaPacific Fund has a beta of 1.0276442, suggesting that its stock price is 3% more volatile than the broader market.

Summary

Schroder Investment Trust - Schroder AsiaPacific Fund beats International Biotechnology on 9 of the 14 factors compared between the two stocks.

How does International Biotechnology compare to Vietnam Enterprise?

International Biotechnology (LON:IBT) and Vietnam Enterprise (LON:VEIL) are both small-cap financial services companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

6.9% of International Biotechnology shares are held by institutional investors. Comparatively, 18.3% of Vietnam Enterprise shares are held by institutional investors. 1.1% of International Biotechnology shares are held by company insiders. Comparatively, 0.2% of Vietnam Enterprise shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

International Biotechnology has a beta of 0.316, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Vietnam Enterprise has a beta of 0.60559064, suggesting that its share price is 39% less volatile than the broader market.

In the previous week, International Biotechnology had 1 more articles in the media than Vietnam Enterprise. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Vietnam Enterprise. International Biotechnology's average media sentiment score of 0.67 beat Vietnam Enterprise's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
International Biotechnology Positive
Vietnam Enterprise Neutral

International Biotechnology has a net margin of 82.27% compared to Vietnam Enterprise's net margin of 67.17%. International Biotechnology's return on equity of 27.35% beat Vietnam Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Vietnam Enterprise 67.17%4.38%-7.53%

International Biotechnology has higher earnings, but lower revenue than Vietnam Enterprise. International Biotechnology is trading at a lower price-to-earnings ratio than Vietnam Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M3.89£37.91M-£3.29N/A
Vietnam Enterprise£81.16M13.04-£4.24M£40.0019.18

Summary

International Biotechnology beats Vietnam Enterprise on 7 of the 13 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

Export
MetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON Exchange
Market Cap£303.64M£2.42B£5.72B£2.77B
Dividend Yield3.31%6.02%5.28%6.12%
P/E Ratio-289.9725.8916.36363.03
Price / Sales3.892,096.701,339.6187,287.69
Price / Cash155.7460.1589.8527.85
Price / Book1.251.376.497.65
Net Income£37.91M£264.62M£1.14B£5.89B
7 Day Performance-3.44%-0.87%-0.61%-0.55%
1 Month Performance-1.24%0.32%1.08%3.07%
1 Year Performance59.53%10.76%19.13%73.33%

International Biotechnology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 954
-1.2%		N/A+62.7%£303.64M£78.01MN/AN/A
JFJ
JPMorgan Japanese
N/AGBX 803
+0.6%		N/A+28.1%£1.25B£245.42M5.39N/A
TMPL
Temple Bar
N/AGBX 396
-0.1%		N/A+27.6%£1.19B£281.60M4.08N/A
IHP
IntegraFin
3.334 of 5 stars		GBX 338.50
+0.9%		GBX 423
+25.0%		+9.2%£1.12B£165.40M21.843,520
SDP
Schroder Investment Trust - Schroder AsiaPacific Fund
N/AGBX 847
+0.4%		N/A+61.6%£1.08B£127.21M9.72N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IBT) was last updated on 6/5/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel